Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels [2]

Thrombosis and Haemostasis

Volumn 94, Issue 5, 2005, Pages 1109-1110

  Rocha Hernando, Eduardo ^a   Gómez Outes, Antonio ^b   González, Javier Martínez ^b   Kakkar, Vijay Vir ^c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Lab Farmaceuticos Rovi S A   (Spain)

^c THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BEMIPARIN; CORTICOSTEROID; DICLOFENAC; DIPYRONE; ESTROGEN; FUROSEMIDE; GLYCEROL; HEPARIN; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; POTASSIUM CHLORIDE; POTASSIUM ION; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ALDOSTERONE BLOOD LEVEL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; LETTER; LONG TERM CARE; MALE; POTASSIUM BLOOD LEVEL; POTASSIUM METABOLISM; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; STUDENT T TEST;

EID: 27844584356     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616815     Document Type: Letter

References (7)

1. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995; 98: 575-86,
2. Koren-Michowitz M, Avni B, Michowitz Y, et al. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf 2004; 13: 299-302.
3. Gheno G, Cinetto L, Savarino C, et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003; 59: 373-7.
4. Canova CR, Fischler MP, Reinhart WH. Effect of low molecular weight heparin on serum potassium. Lancet 1997; 349: 1447-8.
5. Monreal M, Lafoz E, Salvador R, et al. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalemia. Eur J Clin Pharmacol 1989; 37: 415-8.
6. Marcelli JM, Lalau JD, Abourachid H, el. Unlike heparin, low-molecular weight heparin does not suppress aldosterone production. Horm Metab Res 1989; 21: 402.
7. Kakkar VV Gebska M, Kadziola Z, et al. Low-molecular-weight heparin in the acute and long-term treatment of deep-vein trombosis. Thromb Haemost 2003; 89: 574-80.